Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 5 studies | 27% ± 5% | |
| connective tissue cell | 5 studies | 28% ± 11% | |
| endothelial cell | 4 studies | 33% ± 4% | |
| natural killer cell | 4 studies | 19% ± 3% | |
| T cell | 4 studies | 25% ± 6% | |
| conventional dendritic cell | 3 studies | 18% ± 1% | |
| epithelial cell | 3 studies | 44% ± 21% | |
| pericyte | 3 studies | 27% ± 7% | |
| B cell | 3 studies | 36% ± 7% | |
| CD4-positive, alpha-beta T cell | 3 studies | 25% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 3 studies | 30% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 565.71 | 2641 / 2642 | 100% | 16.61 | 705 / 705 |
| thymus | 100% | 789.82 | 653 / 653 | 100% | 16.35 | 604 / 605 |
| prostate | 100% | 820.63 | 245 / 245 | 100% | 9.30 | 501 / 502 |
| esophagus | 100% | 445.73 | 1445 / 1445 | 99% | 7.60 | 182 / 183 |
| uterus | 100% | 815.28 | 170 / 170 | 99% | 11.73 | 455 / 459 |
| kidney | 100% | 533.28 | 89 / 89 | 99% | 9.02 | 892 / 901 |
| skin | 100% | 454.18 | 1809 / 1809 | 99% | 8.97 | 466 / 472 |
| breast | 100% | 556.34 | 459 / 459 | 99% | 8.90 | 1103 / 1118 |
| bladder | 100% | 606.81 | 21 / 21 | 98% | 8.28 | 496 / 504 |
| pancreas | 99% | 314.40 | 325 / 328 | 99% | 8.26 | 176 / 178 |
| intestine | 100% | 520.48 | 966 / 966 | 98% | 8.96 | 516 / 527 |
| adrenal gland | 100% | 366.72 | 257 / 258 | 98% | 10.68 | 226 / 230 |
| stomach | 99% | 295.20 | 354 / 359 | 99% | 7.63 | 283 / 286 |
| lung | 99% | 417.09 | 572 / 578 | 98% | 7.05 | 1129 / 1155 |
| ovary | 100% | 867.50 | 180 / 180 | 97% | 5.39 | 415 / 430 |
| liver | 94% | 175.42 | 212 / 226 | 63% | 2.70 | 254 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 12.22 | 29 / 29 |
| spleen | 100% | 789.22 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 8.98 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 4.79 | 1 / 1 |
| adipose | 100% | 487.29 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 441.29 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| heart | 99% | 282.38 | 849 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 98% | 7.67 | 78 / 80 |
| muscle | 88% | 151.50 | 704 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 47% | 158.89 | 441 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0000398 | Biological process | mRNA splicing, via spliceosome |
| GO_0051028 | Biological process | mRNA transport |
| GO_0071013 | Cellular component | catalytic step 2 spliceosome |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0003730 | Molecular function | mRNA 3'-UTR binding |
| Gene name | HNRNPA1L2 |
| Protein name | Heterogeneous nuclear ribonucleoprotein A1-like 2 (hnRNP A1-like 2) (hnRNP core protein A1-like 2) |
| Synonyms | HNRNPA1L |
| Description | FUNCTION: Involved in the packaging of pre-mRNA into hnRNP particles, transport of poly(A) mRNA from the nucleus to the cytoplasm and may modulate splice site selection. . |
| Accessions | ENST00000357495.5 Q32P51 |